688278 Stock Overview
Engages in research, development, production, and sale of recombinant protein drugs in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Xiamen Amoytop Biotech Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥74.00 |
| 52 Week High | CN¥86.11 |
| 52 Week Low | CN¥46.30 |
| Beta | 0.44 |
| 1 Month Change | 1.19% |
| 3 Month Change | 17.00% |
| 1 Year Change | 47.09% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 70.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688278 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 3.6% | -1.7% | -0.5% |
| 1Y | 47.1% | -19.8% | 9.2% |
Return vs Industry: 688278 exceeded the CN Biotechs industry which returned -19.6% over the past year.
Return vs Market: 688278 exceeded the CN Market which returned 10.8% over the past year.
Price Volatility
| 688278 volatility | |
|---|---|
| 688278 Average Weekly Movement | 8.2% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CN Market | 13.0% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 688278 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688278's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 2,106 | Li Sun | www.amoytop.com |
Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China. The company provides solutions for diseases, such as viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd.
Xiamen Amoytop Biotech Co., Ltd. Fundamentals Summary
| 688278 fundamental statistics | |
|---|---|
| Market cap | CN¥30.10b |
| Earnings (TTM) | CN¥740.69m |
| Revenue (TTM) | CN¥2.60b |
40.6x
P/E Ratio11.6x
P/S RatioIs 688278 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688278 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.60b |
| Cost of Revenue | CN¥179.47m |
| Gross Profit | CN¥2.42b |
| Other Expenses | CN¥1.68b |
| Earnings | CN¥740.69m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.82 |
| Gross Margin | 93.08% |
| Net Profit Margin | 28.54% |
| Debt/Equity Ratio | 0% |
How did 688278 perform over the long term?
See historical performance and comparisonDividends
0.6%
Current Dividend Yield23%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 06:30 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Xiamen Amoytop Biotech Co., Ltd. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hao Wu | Chasing Securities |
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Feifei Xu | China Merchants Securities Co. Ltd. |